← Leaderboards
Qing Li
University Of California, San Francisco
$7,606,806
Attributed
$7,606,806
Total exposure
5
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.4M · FY2008–25$2M$1.5M$1M$500K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$7,606,806 · 5
By mechanism
R01$5,387,458 · 3
T32$1,583,498 · 1
K08$635,850 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of California, San Francisco
Same institution · by research overlap
- Emmanuelle Passegue$22,475,888
- Eric M Pietras$4,768,442
- Nancy Christine Allen$610,378
- Bradley Wayne Blaser$2,492,752
- Gabriel Anthony Reyes$62,226
Others in their field
Top investigators on “Hematopoietic Stem Cells”
- Mary M Horowitz · Medical College Of Wisconsin$222,127,419
- Hans-Peter Kiem · Fred Hutchinson Cancer Center$80,540,126
- David T Scadden · Massachusetts General Hospital$40,987,034
- David A Williams · Indiana Univ-Purdue Univ At Indianapolis$36,503,708
- Irving Lerner Weissman · Stanford University$36,281,548
- Bruce R. Blazar · University Of Minnesota$33,175,355
Research focus
Hematopoietic Stem CellsMediatingSignal TransductionMalignant NeoplasmsGenesCellsInsightKnock-OutMutationMolecularSelf-RenewalLeukemiaPathway InteractionsHematopoieticResponseMyeloproliferative DiseaseOncogenicBloodBiochemicalHematopoietic Stem Cell Self-RenewalKnockout MiceBaseDefectLeukemogenesis
Grant awards (21)
Modulation of Endoplasmic Reticulum Associated Degradation to Support Ex Vivo Expansion of Hematopoietic Stem Cells$503,097
R01 · FY2025 · HL · contact PI
Oncology Research Training Grant$447,844
T32 · FY2025 · CA · contact PI
Modulation of Endoplasmic Reticulum Associated Degradation to Support Ex Vivo Expansion of Hematopoietic Stem Cells$503,097
R01 · FY2024 · HL · contact PI
The role of ER associated degradation (ERAD) in hematopoietic stem cells$480,900
R01 · FY2024 · HL · contact PI
Oncology Research Training Grant$400,650
T32 · FY2024 · CA · contact PI
The role of ER associated degradation (ERAD) in hematopoietic stem cells$490,716
R01 · FY2023 · HL · contact PI
Oncology Research Training Grant$361,107
T32 · FY2023 · CA · contact PI
The role of ER associated degradation (ERAD) in hematopoietic stem cells$490,716
R01 · FY2022 · HL · contact PI
Oncology Research Training Grant$373,897
T32 · FY2022 · CA · contact PI
The role of ER associated degradation (ERAD) in hematopoietic stem cells$490,716
R01 · FY2021 · HL · contact PI
The role of ER associated degradation (ERAD) in hematopoietic stem cells$490,716
R01 · FY2020 · HL · contact PI
Oncogenic Nras signaling in leukemic stem cell transformation$387,500
R01 · FY2020 · HL · contact PI
Oncogenic Nras signaling in leukemic stem cell transformation$387,500
R01 · FY2019 · HL · contact PI
Oncogenic Nras signaling in leukemic stem cell transformation$387,500
R01 · FY2018 · HL · contact PI
Oncogenic Nras signaling in leukemic stem cell transformation$387,500
R01 · FY2017 · HL · contact PI
Oncogenic Nras signaling in leukemic stem cell transformation$387,500
R01 · FY2016 · HL · contact PI
The Role of Oncogenic Ras in Leukemogenesis and Response to Targeted Therapies$127,170
K08 · FY2012 · CA · contact PI
The Role of Oncogenic Ras in Leukemogenesis and Response to Targeted Therapies$127,170
K08 · FY2011 · CA · contact PI
The Role of Oncogenic Ras in Leukemogenesis and Response to Targeted Therapies$127,170
K08 · FY2010 · CA · contact PI
The Role of Oncogenic Ras in Leukemogenesis and Response to Targeted Therapies$127,170
K08 · FY2009 · CA · contact PI
The Role of Oncogenic Ras in Leukemogenesis and Response to Targeted Therapies$127,170
K08 · FY2008 · CA · contact PI